• Caspase-3 Fluorometric Assay Kit for Ferroptosis

  2026-08-15

  Quantify executioner-caspase activity while investigating apoptosis–ferroptosis crosstalk, drug response, and neurodegenerative disease models. This workflow combines DEVD-AFC fluorescence with practical controls and troubleshooting guidance for more defensible caspase activity measurement.

• OMV-Displayed mRNA Antigens for Tumor Vaccination

  2026-08-14

  The reference study developed engineered bacterial outer membrane vesicles that rapidly capture sequence-labeled mRNA antigens and promote their delivery, endosomal escape, and cross-presentation in dendritic cells. Its Plug-and-Display design produced antitumor activity, complete tumor regression in a subset of mice, and durable immune protection, while also highlighting important translational limitations for personalized mRNA vaccine development.

• Multiple Myeloma Cell Lines: Mutations and Drug Resistance

  2026-08-14

  The reference study provides a comprehensive exome-wide map of mutations across human multiple myeloma cell lines, connecting recurrent genomic alterations with disrupted signaling pathways and drug-response phenotypes. Its main practical contribution is a framework for selecting better-characterized models for hematological malignancy research and for interpreting resistance experiments in a genetically informed way.

• Lanabecestat: Designing BACE1 Exposure–Response Assays

  2026-08-13

  Lanabecestat (AZD3293) enables blood-brain barrier-penetrant BACE1 research, but its greatest value may lie in exposure–response assay design rather than maximal enzyme suppression. This article translates neuronal evidence into practical strategies for measuring amyloid-beta reduction alongside synaptic function.

• HyperPFU™ high-fidelity DNA polymerase guide

  2026-08-13

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, and otherwise difficult DNA templates, producing blunt-ended PCR products for cloning or sequencing. It should not be selected when the workflow requires 3′-A overhangs or sticky-end products, and its exact cycling conditions should be validated for each template.

• Caspase-3 Fluorometric Assay Kit in Cell-Death Research

  2026-08-12

  The Caspase-3 Fluorometric Assay Kit provides a quantitative view of executioner-caspase activity in complex cell-death models. This guide interprets DEVD-AFC data alongside mechanistic evidence from hyperthermia–cisplatin research, helping investigators design more informative apoptosis experiments.

• Anti-RPS6 Antibody (MA4974) Research Guide

  2026-08-12

  The Anti-RPS6 antibody MA4974 is an unconjugated mouse IgG1 monoclonal reagent for detecting RPS6 in Western blot, ICC/IF, and immunoprecipitation. This RPS6 monoclonal antibody supports protein-level studies of ribosome-associated signaling while the cited PDAC study supplies biological context for linking biosynthetic growth to LRRC8A–Caveolin-1 signaling.

• ZK53: Practical ClpP Assay Design for Cell Studies

  2026-08-11

  Learn how ZK53 (SKU BA8004) can improve interpretation of cell viability, proliferation, and mitochondrial stress experiments through assay-specific potency data and defined biological mechanisms. This scenario-based guide covers dose selection, species compatibility, ferroptosis studies, and evidence-based product evaluation.

• RSL3, PARP1, and Ferroptosis–Apoptosis Crosstalk

  2026-08-11

  The 2025 study identifies PARP1 as a mechanistic bridge between RSL3-induced ferroptosis and apoptosis, revealing both caspase-dependent PARP1 cleavage and loss of full-length PARP1 through disrupted METTL3-mediated m6A regulation. Its findings suggest that RSL3 can retain pro-apoptotic activity in PARP-inhibitor-resistant tumors and provide a framework for separating ferroptotic and apoptotic outputs in cell-death research.

• Dehydroabietic Acid: From Target to Assay

  2026-08-10

  Dehydroabietic acid offers a practical way to study dual PPAR-α/γ agonism alongside adipocyte gene regulation. This guide connects receptor pharmacology with the targeted CRISPRi findings of Chung et al. to improve assay design, controls, and interpretation in metabolic disorder research.

• IPR-803: From uPAR Binding to Assay Design

  2026-08-09

  IPR-803 is a urokinase receptor inhibitor for dissecting uPAR–uPA biology in invasion, metastasis, and tumor-microenvironment studies. This guide distinguishes direct biochemical activity from context-dependent cellular effects and translates the evidence into better assay decisions.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-08-08

  This guide explains how to use Anti-HMGB1 Rabbit Monoclonal Antibody MA3057 for HMGB1 detection in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is intended for research workflows only; no directly matched paper evidence or diagnostic, therapeutic, or medical-use validation is supplied here.

• BRCA2-Dependent Nascent Strand Maturation with Olaparib

  2026-08-07

  Milano et al. identify a BRCA2- and RAD51-associated pathway that promotes maturation or repair of nascent DNA strands during PARP inhibition. The study links olaparib-induced replication-associated gaps to a post-replicative repair process, refining how PARP inhibitor sensitivity and BRCA-associated cancer targeted therapy may be interpreted.

• Isorhamnetin: Optimizing Oocyte Maturation via PI3K/Akt Path

  2026-08-07

  Isorhamnetin empowers researchers to mitigate oxidative stress and boost oocyte maturation by modulating PI3K/Akt signaling. With APExBIO’s high-purity reagent, precise protocol execution and reliable results are within reach for advanced cellular and reproductive studies.

• Antimycin A4 as an ATP-Citrate Lyase Inhibitor: Workflows &

  2026-08-06

  Antimycin A4 uniquely couples ATP-citrate lyase inhibition with targeted disruption of mitochondrial respiration, making it a dual-action tool for dissecting cellular energy pathways and lipid biosynthesis. This article delivers actionable experimental workflows, troubleshooting guidance, and protocol parameters to maximize reproducibility with APExBIO’s Antimycin A4.

16991 records 1/1133 page Next 12345 下5页 Last page